Alexander J. R.  Bishop, D.Phil.

Currently seeking M.S. & Ph.D. students.

The interest of our lab is to identify and understand mechanisms of damage survival and response. People who inherit a deficiency in damage response are predisposed to develop cancer, usually as children or young adolescents. Further, most cancer treatments are based on damaging cancer cells, so understanding why a chemotherapy works, and for which patients, should lead to more effective (targeted) and less toxic treatments that will increase the cure rate and improve quality of life for cancer survivors. 

My research focus for the last 20 years has been on DNA repair and DNA damage response. For this my lab uses a variety of model systems, including in vivo mouse models and tissue culture systems. DNA damage response and repair is central to normal development and when aberrant, developmental defects, aging phenotypes and cancer ensue. Our work reflects these various aspects of DNA damage response and DNA repair biology, often taking what might be termed a systems biology approach. In general, we apply the knowledge we gain to understand how these processes relate to cancer development and treatment. For example, we recently elucidated that the chemosensitivity observed for Ewing sarcoma is due to protein interactions of the fusion oncogene EWS-FLI1 interfering with the normal biology of EWSR1, resulting in BRCA1 being trapped in a transcription complex and unavailable to promote DNA repair. These findings are a paradigm shift in our understanding of a disease that has largely been studied to understand how the EWS-FLI1 gene expression program drives the etiology of this cancer. This work was published in Nature. We have also published papers delineating how the NRF2 pathway responds to alkylation damage to protect against unfolded protein response, again building on our systems biology approaches. I have a particular interest in the ATM/p53/BRCA1 and NRF2 damage response pathways and how they relate to control of DNA replication, homologous recombination and cancers. Towards this end, we have a tremendous set of resources to evaluate DNA repair and damage response and expertise in RNAi, CRISPR, gene expression, ChIP, protein interactions, bioinformatics, DNA combing, transcription stress and metabolomics available. 

Related diseases: Cancer, Ewing sarcoma, breast cancer, Ataxia telangiectasia, Bloom syndrome, Li-Fraumeni

Techniques: Cell biology, molecular genetics, RNAi, CRISPR, gene expression, ChIP, protein interactions, mouse genetics, cancer xenografts, bioinformatics, DNA combing, transcription assays as well as metabolic flux, oxygen flux assays and metabolomics 

• Professional Background

  Education

  • 2005 - Postdoctoral Fellowship - Genetics - Harvard School of Medicine, Boston, MA, USA
  • 2001 - Postdoctoral Fellowship - Cancer Cell Biology - Harvard School of Public Health, Boston, MA, USA
  • 1998 - PhD - Natural Sciences - Institute of Molecular Medicine, Oxford University, UK
  • 1993 - BSc (Hons) - Biological Sciences (Hons.) - Leicester University

  Highlights

  2020  Became a full member of the NIH MCT1 study section.

  2018 Mays Cancer Center 2018 Discovery of the Year

  2017 Member of the UT Shine Academy

  2015 Member UT Health Science Center of San Antonio’s Academy of Master Teachers

  2015 UT Health Science Center of San Antonio 2015 Presidential Teaching Excellence Award

  2010 Cellular and Structural Biology Award for Excellence in Graduate Student Education

  Additional honors & awards

  Appointments

  • 09/2012 - Associate Professor (tenured) - UT Health at San Antonio, Department of Cell Systems and Anatomy
  • 9/2005 - Principal Investigator - UT Health at San Antonio, Greehey Children`s Cancer Research Institute, San Antonio
  • 5/2005 - Programmatic Member - UT Health at San Antonio, Department of Molecular Medicine, San Antonio
  • 2/2005 - Assistant Professor - UT Health at San Antonio, Cellular & Structural Biology, San Antonio

• Instruction & Training

  • 2/2012 - Present, Post-Doctoral Student Supervision, UT Health - San Antonio
  • 8/2011 - Present, Ph.D. Dissertations Directed, UT Health - San Antonio
  • 8/2011 - Present, Ph.D. Dissertations Directed, UT Health - San Antonio
  • 5/2011 - Present, Membership on Supervising Committee, UT Health - San Antonio
  • 10/2010 - Present, Post-Doctoral Student Supervision, UT Health - San Antonio
  • 9/2010 - Present, Pre-Doctoral Student Supervision, UT Health - San Antonio
  • 6/2010 - Present, Membership on Supervising Committee, UT Health - San Antonio
  • 8/2009 - Present, Membership on Supervising Committee, UT Health - San Antonio
  • 5/2008 - Present, Membership on Supervising Committee, UT Health - San Antonio
  • 8/2007 - Present, Ph.D. Dissertations Directed, UT Health - San Antonio

• Research & Grants

  DNA repair, damage response, Breast Cancer, Pediatric Cancer (Ewing sarcoma), Genetic syndromes, System biology and Metabolism

  The interest of our lab is to identify and understand mechanisms of damage survival. People who inherit a deficiency in damage response are predisposed to develop cancer, usually as children or young adolescents. Further, most cancer treatments are based on damaging cancer cells, so understanding why a chemotherapy works, and for which patients, should lead to more effective and less toxic treatments that will increase the cure rate and improve quality of life for cancer survivors.

  Bishop Lab

  Research profile

  Grants

  STATE:

  Funding Agency: CPRIT RTA RP170345 (PI: Oyajobi, Role: CoI)                           12/01/16 - 11/20/21

  Title: UTHSCSA Cancer Research Training Program

  Role: CoI                                                                                                                                      % Effort: 5

  Total Costs: $3,996,895

  Research Training Award supports for pre-doctoral, post-doctoral trainees, and summer (undergraduate) students, as part of a comprehensive training program covering all aspects cancer research.

   

   

              FEDERAL:

  Funding Agency: NIH NCI 1R01CA241554                                                           Period: 5/2020 - 4/2025

  Title: Dysregulated transcription processes in Ewing sarcoma

  Role: PI                                                                                                                                       % Effort: 20

              Total Costs: $1,634,541

              To determine the consequences of dysregulated transcription regulation in Ewing’s sarcoma.

   

   

  PRIVATE:

  Project #: Collaborative Research Grant (PI: Bishop)                                                      11/2019 - 10/2021

  MERCK EMD Serano                                                                                                                     $538,000

  Title: Assessing the pathological accumulation of R-loops in cancer as an indication of sensitivity to RNA splicing inhibition

  To identify whether R-loops levels can be used to indicate a defect in splicing in different types of cancer and sensitivity to spliceosome inhibitors.

   

  Project #: 614252: Childhood Cancer Research Grant (PI: Bishop)                                01/2019 - 12/2020

  The Andrew McDonough B+ Foundation                                                                                      $150,000

  Targeting RNA processing defects of Ewing sarcoma

  Role: PI                                                                                                                                       % Effort: 15

  To follow up on initial validations of a previously conducted RNAi screen that identified splicing components as synthetic lethal target in Ewing sarcoma. The aim is to then evaluate splicing inhibitors that have the same effect as RNAi depletion of splicing genes and if a therapeutic window exists that can that suggests these inhibitors can be used in the treatment of Ewing sarcoma.

   

   

  Project #:  GCCRI Exploratory experimental fund (PI: Bishop)                             Period: 9/2019 - 8/2020

  Funding Agency: GCCRI funds                                                                                               Total $10,000

  Title: Metabolomics in ATM inhibited cells

  Role: PI                                                                                                                                    % Effort: N/A

  To perform an isotope tracing metabolomics experiment in cells +/- ATM inhibitor to follow glucose and glutamine utilization.

   

   

  Project #:  GCCRI (PI: Bishop) (NCE to 2/2020)                                                   Period: 5/2017 - 4/2019

  Funding Agency: GCCRI funds                                                                                             Total $100,000

  Title: Targeting the transcription dysregulation of Ewing sarcoma

  Role: PI                                                                                                                                    % Effort: N/A

  Total Direct Costs: $100,000

  To validate a previously conducted RNAi screen for synthetic lethal viability in Ewing sarcoma with a focus on determinants of transcription regulation. The goal is to identify therapeutic targets that can be used in the treatment of Ewing sarcoma.

   

   

  Funding Agency: IIMS (PI:Bishop) (NCE to 09/2018)                                       Period: 10/2014 - 09/2015

  Title: Bloom syndrome, chronic stress and cancer

  Role: PI                                                                                                                                    % Effort: N/A

  Total Costs: $50,000

  To determine the metabolic alterations associated with BLM deficiency and whether altering these changes with appropriate interventions can reduce some of the associated cellular and organismal phenotypes with BLM deficiency.

   

  Project #: Ambassador’s Circle Research Award (NCE to 01/2021) Period: 02/2012 - 01/2013

              Funding Agency: GCCRI Ambassador’s Circle

  Title: Targeting nucleotide pools in Bloom’s cells

  Role: Principal Investigator                                                                                                     % Effort: N/A

              PGID: 152219

  Total Direct Costs: $25,000

  We propose to examine the nucleotide pool changes associated with Bloom syndrome cells.

   

   

  FELLOWSHIPS TO STUDENTS AND POSTDOCTORAL FELLOWS:

  Project #: 2020 Greehey Graduate Fellowship Award                                         Period: 09/2020 - 08/2021

              Funding Agency: Graduate Dean’s Office (Predoctoral Traineeship Award to Henry Miller)

  Title: Systems analysis to identify novel vulnerabilities in Ewing sarcoma

  Role: Mentor                                                                                                                            % Effort: N/A

              Total Costs: $33,600

  To identify novel targets to therapeutically treat Ewing sarcoma.

   

   

  Project #: 2020 MCC Graduate Fellowship Award                                             Period: 09/2020 - 08/2021

              Funding Agency: Mays Cancer Center (Predoctoral Traineeship Award to Kevin Kanda)

  Title: Ewing Sarcoma relies on Endogenous Cysteine and Glutamine for Antioxidant Response

  Role: Mentor                                                                                                                            % Effort: N/A

              Total Costs: $33,600

  To elucidate the basis and potential therapeutic value of the metabolic dysregulation of amino acids in Ewing sarcoma.

   

   

  Project #: 2020 CPRIT Training Grant Fellowship Award                                  Period: 10/2020 - 09/2021

  Funding Agency: CPRIT Training Grant (Fellowship Award to Pramiti Mukhopadhyay)

  Title: Dedifferentiation in Ewing sarcoma mediated by R-loops preserves genomic integrity

  Role: Mentor                                                                                                                            % Effort: N/A

  Total Costs: $30,600

  To evaluate replication stress during the dedifferentiation process of Ewing sarcoma.

   

   

  Project #: CDMRP PRCRP Horizon Award                                                        Period: 07/2019 - 06/2021

              Funding Agency: DoD (Predoctoral Traineeship Award to Liesl Lawrence)

  Title: Transcription, R-loops and RNA Splicing in Ewing Sarcoma

  Role: Mentor                                                                                                                            % Effort: N/A

              Total Costs: $150,000

  Understanding and targeting altered regulation of transcription and splicing in Ewing sarcoma.

   

   

  Project #: 2018 AACR-AstraZeneca START                                                      Period: 09/2018 - 08/2021

              Funding Agency: AACR-AstraZeneca (Postdoctoral Traineeship Award to Aparna Gorthi)

              Title: Identifying modifiers of PARP1 inhibitor sensitivity in BRCA-like tumors

  Role: Mentor                                                                                                                            % Effort: N/A

              PGID: 429203

              Total Costs: $225,000

  To identify targets that will improve the efficacy of PARP1 inhibition in tumors that have BRCA1 like phenotypes (eg. Ewing sarcoma).

• Service

  Department

  2017 – present CSA Faculty Forward Committee Chair

  2014 - present  CSB Teaching Currency Committee Member

  2013 - present CSB Teaching Award Committee Member

  2014 - present CSB Postdoc Award Committee Member

  School

  2020 - present IBMS Program Director Search Committee Member

  2020 - present GCCRI Director Search Committee Member

  2020 – present IMBS Curriculum Committee Chair

  2014 – present Cancer Biol Discipline Committee of Graduate Studies Member

  Institutional

  2020 - present Sarcoma Working Group Organizer

  2020 - present Subcommittee to organize GCCRI Symposium 2021 Member

  2019 - present GCCRI Seminar Series Committee Member

  2017 – present UT Shine Awards Committee  Member

  2015 - present CTRC CPRIT Review Committee  Member

  2012 – Present GCCRI Operations Committee Member

  2005 – Present GCCRI Radiation Use and Safety Coordinator

  National Service

  2011 – present  Ewing’s Sarcoma Biology Committee Member in Children's Oncology Group

• Publications

  1. Abraham KJ, Chan JNY, Nein Khosraviani N, Gorthi A, Samman A, Zhao DY, Wang M, Singhania R, Ostrowski LA, Oshidari R, Pietrobon V, Ohh M, Dickson BC, De Carvalho DD, Lee S, Greenblatt JF, Bishop AJR and Mekhail K. Nucleolar RNA polymerase II drives ribosome biogenesis. Nature 2020 Jun 16 (doi: 10.1038/s41586-020-2497-0)
  2. Pan H, Jian M, Ghadiyaram A, Kaur P, Miller HE, Ta H, Liu M, Fan Y, Mahn C, Gorthi A, You C, Piehler J, Riehn R, Bishop AJR, Tao YJ and Wang H. Cohesin SA1 and SA2 are RNA binding proteins that localize to RNA containing regions on DNA. Nucleic Acids Research 2020 Jun 4;48(10):5639-5655. doi: 10.1093/nar/gkaa284, PMID: 32352519
  3. Miller HE, Gorthi A, Bassani N, Lawrence LA, Iskra BS and Bishop AJR, Reconstruction of Ewing Sarcoma Developmental Context from Mass-Scale Transcriptomics Reveals Characteristics of EWSR1-FLI1 Permissibility. Cancers 2020 Apr 11; 12(4):948
  4. Schafer ES, Rau RE, Berg S, Liu X, Minard CG, Bishop AJR, Romero JC, Hicks MJ, Nelson, Jr, MD, Voss S, Reid JM, Fox E, Weigel BJ and Blaney SM. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: a Children’s Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric Blood & Cancer 2019 Nov 14:e28073 PMID 31724813
  5. Lambo S, Gröbner S, Rausch T, Waszak S, Schmidt C, Gorthi A, Romero JC, Mauermann M, Brabetz S, Krausert S, Buchhalter I, Koster J, Sill M, Hübner J, Mack N, Schwalm B, Ryzhova M, Hovestad V, Papillon-Cavanagh S, Chan J, Landgraf P, Ho B, Milde T, Witt O, Ecker J, Sahm F, Sumerauer D, Ellison D, Orr B, Darabi A, Haberler C, Figarella-Branger D, Wesseling P, Schittenhelm J, Taylor M, Gil-da-Costa M, Łastowska M, Grajkowska W, Hasselblatt M, Hauser P, Pietsch T, Uro-Coste E, Bourdeaut F, Masliah-Planchon J, Rigau V, Li XN, Schüller U, Snuderl M, Karajannis M, Giangaspero F, Jabado N, von Deimling A, Jones D, Korbel J, von Hoff K, Lichter P, Huang A, Bishop A, Pfister S, Korshunov A, Kool M. The Molecular Landscape of Embryonal Tumors with Multilayered Rosettes at Diagnosis and Relapse Nature 2019 Dec 12; 576(7786):274-280
  6. Zanotto-Filho A, Rajamanickam S, Loranc E, Masamsetti P, Gorthi A, Romero JC, Tonapi SS, Goncalves RM, Reddick RL, Benavides R, Kuhn J, Chen Y and Bishop AJR. Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Letters 2018 Mar 30;425:101-115 doi: 10.1016/j.canlet.2018.03.037
  7. Barron L and Bishop AJR. P53 and HIS-tag binding. J Proteomics Bioinform 2018 11: 062-067. doi: 10.4172/jpb.1000467 
  8. Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor E, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y and Bishop AJR. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature 2018 Mar 15;555(7696):387-391 This paper was highlighted in Cancer Discovery.
  9. Countryman P, Fan Y, Gorthi A, Pan H, Strickland J, Kaur P, Wang X, Lin J, Lei X, White C, You C, Wirth N, Tessmer I, Piehler J, Riehn R, Bishop AJR, Tao YJ and Wang H. Cohesin SA2 is a sequence independent DNA binding protein that recognizes DNA replication and repair intermediates. J Biol Chem. 2018 Jan 19;293(3):1054-1069
  10. Liu R, Gorthi A, Jin Y, Bishop AJR and Chen Y. Computational Tools for Genome-wide R-loops Identification and Characterization. Int. J. of Computational Biology and Drug Design 2017 Feb; 10(2): 123-136
  11. Zanotto-Filho A, Masamsetti P, Loranc E, Tonapi SS, Gorthi A, Bernard X, Goncalves RM, Moreira JCF, Chen Y and Bishop AJR. Alkylation-induced NRF2 blocks endoplasmic reticulum stress-mediated apoptosis via control of glutathione pools and protein thiol homeostasis. Molecular Cancer Therapeutics 2016 Dec; 15(12):3000-3014 
  12. de Araujo PR, Gorthi A, da Silva AE, Tonapi SS, Vo DT, Burns SC, Qiao M, Uren PJ, Yuan ZM, Bishop AJRand Penalva LOF. Musashi1 impacts radio-resistance in glioblastoma by controlling DNA-PKcs.American Journal of Pathology 2016 Sep;186(9):2271-2278
  13. Zanotto-Filho A, Dashnamoorthy R, Loranc E, de Souza LHT, Moreira JCF, Suresh U, Chen Y, Bishop AJR. Combined gene expression and RNAi screening to identify alkylation damage survival pathways from fly to human. PLoS One 2016 Apr; 11(4): e0153970
  14. Rajamanisckam S, Panneerdoss S, Gorthi A, Timilsina S, Kovalsky D, Hanes M, Vadlamudi R, Chen Y, Bishop AJ, Arbiser JL and Rao MK. FOXM1-Mediated DNA repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis Clinical Cancer Research 2016 Feb; 
  15. Zanotto-Filho A, Braganhol E, Klafke K, Figueiró F, Terra SR, Paludo FJ, Morrone M, Bristot IJ, Battastini AM, Forcelini CM, Bishop AJR, Gelain DP, Moreira JCF. Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. Cancer Letters 2015 Mar; 358(2): 220-231
  16. Brown AD, Sager B, Gorthi A, Tonapi SS, Brown EJ, Bishop AJR. ATR suppresses endogenous DNA damage and allows completion of homologous recombination repair. PLoS One 2014 Mar; 9(3): e91222
  17. Karia B, Martinez JA, Bishop AJR. Induction of Homologous Recombination Following in uteroExposure to DNA-Damaging Agents. DNA Repair 2013 Nov; 12(11):912-921
  18. Lei C, Tamim S, Bishop AJR, Ruan J. Fully automated protein complex prediction based on topological similarity and community structure. Proteome Science 2013 Nov; 11(Suppl 1):S9
  19. Kassan M, Choi S, Galan M, Bishop AJR, Umezawa K, Trebak M and Matrougui K. NFκB Impairs Vascular Function Through PARP-1, SP-1 and COX2-Dependent Mechanisms in Type 2 Diabetes. Diabetes 2013 Jun; 62(6): 2078-2087
  20. Hsu A. F-S, Serpedin E, Hsiao T-H, Bishop AJR, Dougherty ER and Chen Y. Reducing confounding and suppression effects in TCGA data: an integrated analysis of chemotherapy response in ovarian cancer. BMC Genomics 2012 Oct; 13(Suppl 6): S13
  21. Doderer M, Anguiano Z, Suresh U, Ravi D, Bishop AJR and Chen Y. Multisource Biological Pathway Consolidation. BMC Genomics 2012 Oct; 13(Suppl 6): S18
  22. Kim TM, Ko JH, Hu L, Kim SA, Bishop AJR, Vijg J, Montagna C and Hasty P. RAD51 Mutations Cause Replication Defects and Chromosomal Instability. Molecular and Cellular Biology 2012 Sep; 32(18): 3663-3680
  23. Lee IH, Cao L, Kawai Y, Fergusson MM, Liu J, Rovira I, Bishop AJR, Motoyama N, Komatsu M and Finkel T. Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science 2012 Apr; 336(6078): 225-228
  24. Zimmer SN, Lemieux ME, Karia BP, Day C, Zhou T, Zhou Q, Kung AL, Suresh U, Chen Y, Kinney MC, Bishop AJR, Rebel VI. Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative disease Experimental Hematology 2012 Apr; 40(4): 295-306
  25. Lin S, Yu L, Yang J, Karia B, Bishop AJR, Jackson J, Lozano G, Copland JA, Mu X, Sun B and Sun L-Z. Mutant p53 disrupts the role of ShcA in balancing the Smad-dependent and -independent signaling activity of TGF-β. Journal of Biological Chemistry 2011 Dec; 286(51): 44023-44034
  26. Brown AD, Claybon AB, Bishop AJR. A conditional mouse model for measuring the frequency of homologous recombination events in vivo in the absence of essential genes. Molecular and Cellular Biology 2011 Sep; 31(17):3593-602
  27. Claybon AB and Bishop AJR. Dissection of the mouse eye for a wholemount of the retinal pigment epithelium http://www.jove.com/details.stp?id=2563 J Vis Exp 2011 Feb; 48
  28. Ravi D, Chen Y, Karia B, Brown A, Gu TT, Li J, Carey MS, Hennessy BT and Bishop AJR. 14-3-3 expression effects G2/M response to oxygen and correlates with ovarian cancer metastasis. PLoS One2011 Jan;  e15864
  29. Claybon AB, Karia B, Bruce C and Bishop AJR. PARP1 suppresses homologous recombination events in mice in vivo Nucleic Acids Research 2010 Jul; 38: 7538-7545
  30. Brown AD, Claybon AB and Bishop AJR. Mouse WRN Helicase Domain Is Not Required for Spontaneous Homologous Recombination-Mediated DNA Deletion. Journal of Nucleic Acids 2010, Article ID 356917, 6 pages
  31. Wiles A, Doderer M, Ruan J, Gu TT, Ravi D, Blackman B and Bishop AJR. Building and Analyzing Protein Networks by Cross-species Comparisons. BMC Systems Biology 2010; 4(1):36
  32. Ravi D, Wiles AM, Bhavani S, Ruan J, Leder P and Bishop AJR. A network of conserved damage survival pathways revealed by a genomic RNAi screen. PLoS Genetics 2009 Jun: 100052-100052.
  33. Wiles AM, Ravi D, Selvaraj B and Bishop AJR. An analysis of normalization methods for Drosophila RNAi genomic screens and development of a robust validation scheme Journal of Biomolecular Screening 2008 Aug; 13(8):777-784.
  34. Bishop AJR, Kosaras B, Hollander MC, Fornace A, Sidman RL and Schiestl RH. p21 controls patterning but not homologous recombination in RPE development. DNA Repair (Amst) 2006 Jan; 5(1):111-120.
  35. Leder A, McMenamin J, Fontaine K, Bishop AJR, and Leder P. zeta-/- Thalassemic mice are affected by two modifying loci and display unanticipated somatic recombination leading to inherited variation. Hum Mol Genet 2005 Mar; 14(5):615-625.
  36. Secretan MB, Scuric Z, Oshima J, Bishop AJR, Howlett NG, Yau D and Schiestl RH. Effect of Ku86 and DNA-PKcs deficiency on non-homologous end-joining and homologous recombination using a transient transfection assay. Mutat Res 2004 Oct; 554(1-2):351-364.
  37. Reliene R, Bishop AJR, Li G, and Schiestl RH. Ku86 deficiency leads to reduced intrachromosomal homologous recombination in vivo in mice. DNA Repair (Amst) 2004 Feb; 3(2):103-111.
  38. Bishop AJR, Hollander MC, Kosaras B, Sidman RL, Fornace AJ and Schiestl RH. Atm-, p53-, and Gadd45a-deficient mice show an increased frequency of homologous recombination at different stages during development. Cancer Res 2003 Sep;  63(17):5335-5343.
  39. Leder A, Lebel M, Zhou F, Fontaine K, Bishop AJR, Leder P. Genetic interaction between the unstable v-Ha-Ras transgene (Tg.AC) and the murine Werner syndrome gene: Transgene instability and tumorigenesis Oncogene 2002 Sep; 21(43):6657-6668.
  40. Bishop AJR, Kosaras B, Carls N, Sidman RL and Schiestl RH. Susceptibility of proliferating cells to benzo[a]pyrene-induced homologous recombination in mice. Carcinogenesis 2001 Apr; 22(4):641-649.
  41. Bishop AJR, Kosaras B, Sidman RL and Schiestl RH. Benzo(a)pyrene and X-rays induce reversions of the pink-eyed unstable mutation in the retinal pigment epithelium of mice. Mutat Res 2000 Dec; 457(1-2):31-40.
  42. Bishop AJR, Louis EJ and Borts RH. Minisatellite variants generated in yeast meiosis involve DNA removal during gene conversion. Genetics 2000 Sep; 156(1):7-20.
  43. Bishop AJR, Barlow C, Wynshaw-Boris AJ and Schiestl RH. Atm deficiency causes an increased frequency of intrachromosomal homologous recombination in mice. Cancer Res 2000 Jan; 60(2):395-399.
  44. Aubrecht J, Secretan MB, Bishop AJR and Schiestl RH. Involvement of p53 in X-ray induced intrachromosomal recombination in mice. Carcinogenesis 1999 Dec; 20(12):2229-2236.
  45. Gorthi A and Bishop AJR. Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response. Molecular and Cellular Oncology 2018 May 29;5(4):e1465014
  46. Zhou T, Chen P, Gu J, Bishop AJR, Scott LM, Hasty P and Rebel VI. Potential Relationship between Inadequate Response to DNA Damage and Development of Myelodysplastic Syndrome. International Journal of Molecular Sciences 2015 Jan; 16(1):966-989
  47. Zhou T, Hasty P, Walter CA, Bishop AJR, Scott LM and Rebel VI Myelodysplastic Syndrome: an inability to appropriately respond to damaged DNA? Experimental Hematology 2013 Aug; 41(8):665-674
  48. Ravi D and Bishop AJR. RNA interference and functional genomics: From genes to discovery Icfai Journal of Biotechnology 2008 Sep; 2(3):52-62.
  49. Reliene R, Bishop AJR and Schiestl RH.  Involvement of homologous recombination in carcinogenesis. Adv Genet 2007 Jan; 58:67-87. 
  50. Bishop AJR and Schiestl RH.  Role of homologous recombination in carcinogenesis. Exp Mol Pathol2003 Apr; 74(2):94-105.
  51. Bishop AJR and Schiestl R. Homologous recombination and its role in carcinogenesis Journal of Biotechnology and Biomedicine 2002; 2(2):75-85.
  52. Bishop AJR and Schiestl R. Homologous recombination and its role in carcinogenesis Biochemica et Biophysica ACTA - Reviews on Cancer 2001; 147(3):109-121.
  53. Bishop AJR and Schiestl R. Homologous recombination as a mechanism for genome rearrangements: environmental and genetic effects. Hum Mol Genet 2000; 9(16):2427-2434.
  54. Zanotto-Filho A, Bishop AJR and Moreira JCF.  Curcumin: A broad spectrum inhibitor targeting pathways relevant to glioblastomas In: Curcumin: Synthesis, Emerging Role in Pain Management and Health Implications. Nova Science Publishers, Inc.; 2014. p. 409-434.
  55. Ravi D and Bishop AJR. Identification of genes required for damage survival using a cell based RNAi screen against the Drosophila genome In: DNA Repair Protocols, Third Edition; 2012
  56. Brown AD, Karia B, Wiles AM and Bishop AJR. The intertwining of DNA damage response pathway components and homologous recombination repair In: Genetic Recombination Research Progress. Hauppauge, NY, USA: Nova Science Publishers, Inc.; 2008. p. 1 - 68.
  57. Reliene R, Bishop AJR, Aubrecht J and Schiestl RH.  In vivo DNA deletion assay to detect environmental and genetic predisposition to cancer In: Alan Waldman. Genetic Recombination Reviews and Protocols. Totowa, NJ: Humana Press; 2004. p. 125 - 139.
  58. Hsu A. F-S, Serpedin E, Hsiao T-H, Bishop AJR, Dougherty ER and Chen Y. Identifying Genes Associated with Chemotherapy Response in Ovarian Carcinomas Based on DNA Copy Number and Expression Profiles, IEEE Workshops on Genomic Signal Processing and Statistics 2011 (GENSIPS2011), Dec 4-6, 2011, San Antonio, TX. (Also published in a Special Issue of BMC Genomics, 2011 following additional reviews)
  59. Doderer M, Anguiano Z, Suresh U, Ravi D, Bishop AJR and Chen Y. Multisource Biological Pathway Consolidation, IEEE Workshops on Genomic Signal Processing and Statistics 2011 (GENSIPS2011), Dec 4-6, 2011, San Antonio, TX. (Also published in a Special Issue of BMC Genomics, 2011 following additional reviews)

Related media